Bernard Ravina Sells 2,451 Shares of Voyager Therapeutics Inc (VYGR) Stock

Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 2,451 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $18.24, for a total value of $44,706.24. Following the completion of the sale, the insider now directly owns 4,902 shares of the company’s stock, valued at approximately $89,412.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bernard Ravina also recently made the following trade(s):

  • On Wednesday, January 10th, Bernard Ravina sold 3,630 shares of Voyager Therapeutics stock. The stock was sold at an average price of $16.40, for a total value of $59,532.00.
  • On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.63, for a total value of $74,828.70.

Voyager Therapeutics Inc (NASDAQ:VYGR) traded up $0.22 on Tuesday, reaching $18.90. The company had a trading volume of 145,801 shares, compared to its average volume of 300,490. The firm has a market capitalization of $571.75, a PE ratio of -6.58 and a beta of 4.04. Voyager Therapeutics Inc has a 52-week low of $8.10 and a 52-week high of $25.99.

VYGR has been the subject of several recent analyst reports. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 target price (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 target price for the company. Robert W. Baird initiated coverage on Voyager Therapeutics in a research report on Monday, October 30th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Wedbush reaffirmed a “positive” rating and issued a $31.00 target price (down previously from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating to the company. Voyager Therapeutics presently has an average rating of “Buy” and a consensus price target of $26.90.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. Schwab Charles Investment Management Inc. boosted its position in Voyager Therapeutics by 0.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after purchasing an additional 114 shares during the last quarter. Rhumbline Advisers boosted its position in Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Voyager Therapeutics by 20.9% during the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after purchasing an additional 9,207 shares during the last quarter. Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 9.3% during the second quarter. Wells Fargo & Company MN now owns 91,384 shares of the company’s stock valued at $819,000 after purchasing an additional 7,807 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in Voyager Therapeutics by 24.7% during the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after purchasing an additional 5,081 shares during the last quarter. 36.42% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Bernard Ravina Sells 2,451 Shares of Voyager Therapeutics Inc (VYGR) Stock” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/13/bernard-ravina-sells-2451-shares-of-voyager-therapeutics-inc-vygr-stock.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply